Showing results (111-120 of 186) with videos related to
Sort By:
Pageof 19
Hepatology International|March 5, 2020
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter studyAkito Nozaki, Masanori Atsukawa, Chisa Kondo, et al.Hepatology International|September 8, 2022
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumabTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 6, 2023
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysisTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|January 6, 2025
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk ModelsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Liver Cancer|August 21, 2023
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter AnalysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Journal of Gastroenterology and Hepatology|May 26, 2023
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Medicine|October 13, 2022
Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Oncology|September 14, 2022
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Hepatology International|June 24, 2022
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Oncology|December 1, 2022
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus BevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Pageof 19